1.Effect of clinical pharmacist interventions on the rational use of antibiotics
Wei HU ; Jinhui GUO ; Fengqi TIAN ; Rupin LIU ; Youliang LI ; Jinxia XU ; Ke WANG ; Qiang WANG ; Zhicheng DONG
Chinese Journal of Primary Medicine and Pharmacy 2015;(8):1152-1153
Objective To study the effect of clinical pharmacist interventions on the rational use of antibiot-ics.Methods 1 000 hospitalized patients before the implementation of intervention in April 2012 to April 2013 (control group)and the other 1 000 cases of hospitalized patients in May 2013 to May 2014 after the implementation of the intervention (study group)were selected,the antibiotics use rate,hospitalization time and cost,cost of using antibacterial drugs were compared between the two groups.Results The antibiotics use rate of the study group was 56.0%(560/1 000),significantly lower than 78%(780/1 000)of the control group,with significant differences between the two groups(χ2 =11.089,P=0.032),the hospitalization time,cost of using antibacterial drugs of the study group were (12.6 ±0.8)days,(912.2 ±13.2)yuan,significantly better than (16.9 ±0.7)days,(1 528.1 ± 32.5)yuan of the control group,with significant differences between the two groups (t=9.892,10.142,P=0.028, 0.014);The two groups of hospitalization expenses showed no statistical significance (t =4.984,P =0.072 ). Conclusion Clinical pharmacist intervention has a positive effect on the application of antibacterial drugs,which can significantly reduce the use of antimicrobial drugs and reduce the hospitalization days.
2.Literature Analysis of Hepatotoxicity Induced by Quinolones
Jinlan YANG ; Sheng WANG ; Wei HU ; Rupin LIU ; Shaojun SHI ; Yu ZHANG ; Sanlan WU
China Pharmacy 2019;30(2):244-249
OBJECTIVE: To investigate the characteristics and regularity of hepatotoxicity induced by quinolones, and to provide reference for clinical use of drug safely. METHODS: Using “quinolone” “floxacin” “hepatotoxicity” “hepatic injury”as retrieval words, relevant literatures about hepatotoxicity induced by quinolones were retrieved from domestic and foreign databases as CNKI, Wanfang, VIP, PubMed (during database establishment to 31th, Dec. 2017). Those literatures were summarized and analyzed. RESULTS: A total of 59 valid literatures were collected, including 61 cases of hepatotoxicity induced by quinolones, 8 types of drugs as ciprofloxacin, moxifloxacin, ofloxacin, lomefloxacin, norfloxacin, levofloxacin, gatifloxacin and enoxacin. Ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin were the most common drugs that caused hepatotoxicity, involving 19, 13, 11, 7 cases, respectively; accumulative constitute ratio was 81.97%. The ratio of male to female was 1.54 ∶ 1, and hepatotoxicity always happened at the age of 61 to 80 (30 cases, 49.18%). Primary diseases of 46 cases were single disease (75.41%), and mainly were infection of respiratory system and urogenital system. There were 15 cases of combined disease (24.59%). Thirty-one cases used quinolones alone, most of which was ciprofloxacin. There were 30 cases of drug combination. Thirty-four cases were given drug intravenously and mainly were domestic cases. The hepatotoxicity first occurred within 10 minutes after administration and at the latest 8 weeks after administration. Forty-nine patients suffered from hepatotoxicity within 10 days after medication, accounting for 80.33%. Besides general fatigue, nausea and vomiting, clinical symptoms also included abnormal elevation of alanine aminotransferase, aspartate aminotransferase and total bilirubin,etc. Fifty-four patients were improved after withdrawal or symptomatic treatment, while 7 patients died. The results of causality evaluation of drug-induced hepatic injury showed that there were 4 probably association cases, 45 likely association cases and 12 possible association cases. CONCLUSIONS: The hepatotoxicity caused by quinolones is related to drug variety, patient’s age, primary disease, drug combination and route of administration, and mostly occurs within 10 days after administration. Great importance should be attached to patient’s liver function indexes, strengthen medication monitoring, and carefully combined use of drugs.